An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines

Boaventura Antônio dos Santos,1 Tani Schilling Ranieri,2 Marilina Bercini,2
Maria Tereza Schermann,2 Sirlei Famer,2 Renate Mohrdieck,2
Teresinha Maraskin,3 and Mário Bernardes Wagner1

Objective. To compare the incidence of adverse events following the administration of three commercially available measles-mumps-rubella (MMR) combination vaccines.

Methods. A randomized double-blind clinical trial was performed in 1996 that involved a total of 10,142 students 6–12 years of age in the state of Rio Grande do Sul, in Brazil. An MMR vaccine containing the Edmonston-Zagreb, Leningrad-Zagreb, and RA 27/3 strains (“vaccine A”) was administered to 2,226 students (21.9% of the total); an MMR vaccine with the Moraten, Jeryl Lynn, and Wistar 27/3 strains (“vaccine B”) was administered to 2,216 children (21.8%); and an MMR vaccine containing the Schwartz, Urabe AM-9, and Wistar 27/3 strains (“vaccine C”) was given to 2,179 students (21.5%). A control group of 3,521 students (34.7%) was not vaccinated. Both the vaccinated subjects and the control subjects were followed daily for 30 days to detect any clinical manifestations.

Results. Adverse events were more frequent in the vaccinated children than in the control group (P < 0.01). In terms of causing parotitis, vaccine A had a relative risk (RR) of 5.72 (95% confidence interval (CI) = 3.11–10.54) when compared with vaccine B, and an RR of 2.33 (95% CI = 1.52–3.58) when compared with vaccine C. Vaccine A was also associated with an increased risk of lymphadenopathy when compared with vaccine B (RR = 3.11; 95% CI = 1.78–5.45) and with vaccine C (RR = 2.22; 95% CI = 1.35–3.66). Vaccine C was associated with an increased risk of parotitis when compared with vaccine B (RR = 2.46; 95% CI = 1.26–4.80). Three cases of aseptic meningitis were detected among the children in the study group, but only one case of vaccine-related aseptic meningitis was identified, among the children receiving vaccine A.

Conclusions. The three MMR vaccines that we studied are associated with different risks of adverse events. We found vaccine A to cause more reactions than the two other vaccines, especially vaccine B. In addition, vaccine A presented both a temporal and a cause-and-effect association with one case of aseptic meningitis. We hope that this study will contribute information that can be used in choosing MMR vaccines with safe and effective strains, especially for mass vaccination strategies.

Key words Vaccination, measles, mumps, rubella, Brazil.
Since the 1960s several vaccines of differing composition and origin have been available individually against measles, mumps, and rubella. Subsequently, such vaccines have been combined for use as a single measles-mumps-rubella (MMR) combination vaccine (1, 2). Depending on the type of strain used and the individual response to the vaccine, administration of such combinations can cause adverse events, which can range from mild and relatively frequent to severe but rare reactions (1, 3, 4). The most common adverse events associated with the measles strains are fever, occurring in 5% to 15% of the vaccinees, and skin rash, with a 5% incidence (1, 2). As to mumps strains, post-vaccination events are rare, with fever and parotitis being the most frequent ones. Aseptic meningitis has been a major problem, and several studies have demonstrated a clear association with the more reactogenic strains (1, 3, 5–7). Regarding the rubella strain, fever, skin rash, and/or lymphadenopathy occur in 5% to 15% of the vaccinees, while arthritis is the most common side effect in postpubertal women, occurring in 13% to 15% of them (2, 4).

In Brazil one of the objectives of the National Immunization Program is to better control rubella and mumps and to eradicate measles. To eradicate measles, the main strategy used is mass vaccination campaigns, with the measles vaccination often combined with strains of rubella and mumps. A monovalent vaccine against measles has been included in the primary immunization schedule in the country since 1973, and the MMR combination vaccine has been gradually introduced since the early 1990s, state by state.

In an attempt to collect data on adverse events associated with three different MMR combination vaccines, a clinical trial was carried out in 1996 that included more than 10 000 students from Porto Alegre and Santa Maria, two cities that are in Rio Grande do Sul, the southernmost state of Brazil. The three vaccines used in the study (labeled as “A,” “B,” and “C”) had the compositions (strains) shown in Table 1.

During our bibliographic review before the clinical trial, we found no studies that compared these three combination vaccines and only a few articles about vaccine A (8–11). Before our study, three Brazilian states were using vaccine C, a choice that had been made by local public health administrators.

The Ministry of Health of Brazil supported this research, with a particular interest in estimating the incidence of adverse events related with these vaccines, especially vaccine A. At the time of our study, vaccine A was being used in a few countries (8–11), but it had not yet been used in Brazil. For the National Immunization Program of Brazil, the goal was to develop information to apply in choosing more effective, safer vaccines to use primarily in mass and follow-up vaccination campaigns, in line with the recommendations of the Pan American Health Organization (12).

**MATERIALS AND METHODS**

**Study design**

We conducted a double-blind randomized clinical trial in order to evaluate the adverse reaction potential of three MMR combination vaccines in schoolchildren 6 to 12 years old from Porto Alegre and Santa Maria. A stratified sampling design was used, wherein the study population was selected in proportion to the relative population of the two cities: 85.2% for Porto Alegre and 14.8% for Santa Maria. Children assigned to each sample were randomly selected from 70 public and private schools, 47 from Porto Alegre and 23 from Santa Maria. Four groups were formed: one group for each of the three MMR vaccines, and a control group which did not receive an MMR vaccination.

Children were excluded from the trial if they presented any of the following contraindications to the MMR vaccine: congenital or acquired immunodeficiency; malignant neoplasia; high-dose

**TABLE 1. Vaccines used in study evaluating the adverse reaction potential of three measles-mumps-rubella combination vaccines, Rio Grande do Sul, Brazil, 1996**

<table>
<thead>
<tr>
<th>Vaccine code</th>
<th>Vaccine/Manufacturer</th>
<th>Strains</th>
<th>Doses</th>
<th>Other constituents</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Tresivac®/Serum Institute of India</td>
<td>Edmonston-Zagreb</td>
<td>5 000 TCID₅₀ᵃ</td>
<td>Not described by manufacturer</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Leningrad-Zagreb</td>
<td>5 000 TCID₅₀ ᵇ</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wistar RA 27/3</td>
<td>4 000 PFUsᵇ</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>M-M-R II®/Merck-Sharp-Dohme</td>
<td>Moraten</td>
<td>1 000 TCID₅₀</td>
<td>Sorbitol and hydrolyzed gelatin traces</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jeryl Lynn</td>
<td>5 000 TCID₅₀</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wistar RA 27/3</td>
<td>1 000 TCID₅₀</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Trimovax®/Institute Pasteur Merieux</td>
<td>Schwarz</td>
<td>1 000 TCID₅₀</td>
<td>Neomycin and kanamycin, hydrolyzed gelatin, and phenol red traces</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Urabe AM-9</td>
<td>5 000 TCID₅₀</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wistar RA 27/3</td>
<td>1 000 TCID₅₀</td>
<td></td>
</tr>
</tbody>
</table>

ᵃ TCID₅₀ = tissue culture infectious dose for 50% of tissue culture.
ᵇ PFUs = plaque-forming units.
treatment with corticoids or other immunosuppressive drugs; previous history of anaphylactic reaction secondary to the use of neomycin or to egg intake; pregnancy; use of human immunoglobulin, whole blood, or plasma within the previous three months; and moderate to severe acute febrile conditions at the time of enrollment.

A questionnaire designed to collect individual information about the children (age, sex, vaccination background, previous diseases, family income, etc.) was used. In each school, children were recruited according to the age groups of the study. After obtaining informed consent from the parents or other legal representatives, children were randomized to one of three vaccine groups (A, B, or C). The vaccine bottles were labeled so as to prevent their identification by the vaccinees, the vaccinators, the researchers, and the nurses who managed the follow-up. The control group (children who were not vaccinated) was homogenous in relation to the vaccinated children. Including a control group was considered important since the study was carried out during a period of seasonal outbreaks of the three diseases. The main goal with the control group was to determine the occurrence of systemic manifestations since those students had not received an injectable placebo.

Statistical analysis

The projected sample size, approximately 2,200 children per vaccinated group and 3,500 nonvaccinated controls, was designed to allow detection of two-fold increases in events as rare as 1.5%, with levels of at least \( \alpha = 0.05 \) and \( \beta = 0.10 \). That is, the sample size was estimated to have a power of 90% to detect a two-fold or larger increase in frequencies as low as 1.5%, and 80% power in frequencies as low as 1.2%.

Differences among the groups in values of continuous variables (e.g., age) were compared using means and standard deviations, via analysis of variance, while those for categorical variables (e.g., adverse events, expressed as percentages) were compared using the chi-square test. Additionally, we calculated the relative risk (RR) of adverse events and the 95% confidence interval (CI) for that. Data were processed and analyzed with the help of two software packages, SPSS version 6.0 (SPSS Inc., Chicago, Illinois, United States of America) and Epi Info version 6.04B (Centers for Diseases Control and Prevention, Atlanta, Georgia, United States).

Because of the limitations of our sample size, we did not try to determine what the incidence rate of vaccine-associated adverse events would be in larger population groups for rare events such as aseptic meningitis and thrombocytopenic purpura.

Vaccines used

As mentioned earlier, the three vaccines used in this study were labeled as “A”, “B,” and “C,” and they had the composition (strains) as shown in Table 1. Each dose of the three vaccines corresponded to 0.5 mL and was injected in the arm subcutaneously, at the level of the deltoid muscle. Antipyretics were not routinely used after the vaccinations.

Field work and data collection

Several meetings with parents, teachers, and professionals from government health reference units (hospitals and outpatient units) were held. At these meetings, the study design and the activities to be carried out were presented.

The field work consisted of vaccine delivery in the schools and monitoring of the signs and symptoms among the participating children. The field work was performed by selected health professionals who had received a total of 40 hours of training from the researchers. The professionals were selected from the health services and were paid for their work.

The teams that delivered the vaccines included a coordinator (a nurse), the vaccine delivery staff (nursing assistants), an administrative support staff, and a driver. They worked from 26 to 30 August 1996 in Porto Alegre and from 9 to 12 September in Santa Maria.

The monitoring of signs and symptoms was carried out by a team of nurses. The monitoring was begun with each vaccine’s administration, in order to observe immediate reactions, and it was continued daily over the following 30 days. The nurses visited the schools and recorded, on a standard form, the clinical events observed in both the vaccinated and control children, regardless of the events’ causal relationship with the vaccine. Home and hospital visits were scheduled in order to complement that school-based data collection, such as when a student was absent from school or was hospitalized. Reactions that had taken place on a Saturday or Sunday were recorded by the nurses on Monday. Each adverse effect was defined in an instruction manual that was the basis for the nurses’ training. Nurse teams met on a weekly basis with the researchers in order to discuss the recorded information and to solve any administrative problems.

From a subgroup of 640 children, selected from 6 of the 70 schools, paired blood samples were collected before the immunization and 30 days after it. This step made it possible to compare the children’s previous immunological status and the post-immunization response.

Ethical issues

The protocol of this study was reviewed and approved by the scientific research and health ethics councils at both the Clinics Hospital of Porto Alegre and the Federal University of Santa Maria. The parents or other legal representatives received all the information about the vaccines used in this trial and the potential risks for adverse events and signed an informed consent form allowing their children to participate in the study.
RESULTS

A total of 10 142 schoolchildren participated in the study. Out of this total, 6 621 were vaccinated in three groups: 2 226 of them (21.9% of the total sample) received vaccine A, 2 216 (21.8%) received vaccine B, and 2 179 (21.5%) received vaccine C. The control group was made up of 3 521 children (34.7% of the total sample). Age and sex variables were homogeneously distributed among the four groups (the three vaccinated groups and the one control group). There was an age range of 6 to 12 years among the participants, and the entire group contained 54% females and 46% males. During the observational period, 1 186 of the vaccinated children (17.9% of them) presented some kind of adverse event, compared with only 168 controls (4.8% of the control group).

Of the children from the four groups presenting with an adverse event, 45% of them presented with only one sign or symptom. For the students who had been vaccinated, the most commonly reported local adverse events are shown in Table 2. Pain at the injection site, in most cases persisting for just one day, was the most frequently reported symptom, followed by induration.

As shown in Table 3, headache was the most common systemic adverse event reported by the three vaccinated groups; it had a mean duration of one day. Fever was the second most commonly reported systemic adverse event, persisting in most cases for one day, with all cases resolving within five days.

We compared the three vaccines in terms of the time interval between vaccination and emergence of headache, fever, and increased parotid volume. We found that both fever and headache occurred within five days after vaccination.

The incidence of increased parotid volume with vaccine A was 2.3 times as high as with vaccine C and 5.7 times as high as with vaccine B. The peak incidence of increased parotid volume occurred between 15 and 19 days after immunization with vaccines A and C. As to vaccine B, that peak incidence occurred mostly between 5 and 9 days and 20 and 24 days after vaccination. A low incidence of skin rash was observed in the vaccinated groups. Eleven cases occurred in children receiving vaccine A, 9 with vaccine B, and 16 with vaccine C, with the rash lasting up to 6 days. The peak incidence of skin rash occurred 5 to 9 days after vaccination.

The incidence of lymphadenopathy reported after the use of vaccine A was

<table>
<thead>
<tr>
<th>Local adverse event</th>
<th>A (n = 2 226)</th>
<th>B (n = 2 216)</th>
<th>C (n = 2 179)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
<td>No.</td>
</tr>
<tr>
<td>Pain at injection site</td>
<td>54</td>
<td>2.4</td>
<td>45</td>
</tr>
<tr>
<td>Induration</td>
<td>22</td>
<td>1.0</td>
<td>11</td>
</tr>
</tbody>
</table>

* *χ² test; P < 0.001 between vaccines A and B and between vaccines A and C.*

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>A (n = 2 226)</th>
<th>B (n = 2 216)</th>
<th>C (n = 2 179)</th>
<th>Control group (n = 3 521)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No.</td>
<td>%</td>
<td>No.</td>
<td>%</td>
</tr>
<tr>
<td>Headache</td>
<td>202</td>
<td>9.1</td>
<td>187</td>
<td>8.4</td>
</tr>
<tr>
<td>Fever</td>
<td>122</td>
<td>5.5</td>
<td>105</td>
<td>4.7</td>
</tr>
<tr>
<td>Nausea</td>
<td>29</td>
<td>1.3</td>
<td>36</td>
<td>1.6</td>
</tr>
<tr>
<td>Vomiting</td>
<td>37</td>
<td>1.7</td>
<td>26</td>
<td>1.2</td>
</tr>
<tr>
<td>Cough</td>
<td>28</td>
<td>1.3</td>
<td>22</td>
<td>1.0</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>31</td>
<td>1.4</td>
<td>18</td>
<td>0.8</td>
</tr>
<tr>
<td>Skin rash</td>
<td>21</td>
<td>0.9</td>
<td>13</td>
<td>0.6</td>
</tr>
<tr>
<td>Increased parotid volume</td>
<td>69</td>
<td>3.1</td>
<td>12</td>
<td>0.5</td>
</tr>
</tbody>
</table>

* *χ² test; P < 0.001 between vaccines A and B and A and C.*

* *χ² test; P < 0.001 between vaccines C and B.*

---

**TABLE 2.** Most frequent local adverse events reported over 30-day follow-up period after vaccination, in study evaluating the adverse reaction potential of three measles-mumps-rubella combination vaccines, Rio Grande do Sul, Brazil, 1996

**TABLE 3.** Main systemic adverse events reported after vaccination compared with the control group over a 30-day period, in study evaluating the adverse reaction potential of three measles-mumps-rubella combination vaccines, Rio Grande do Sul, Brazil, 1996
During the 30-day follow-up period, joint reactions primarily included transient arthralgia, with no episodes of arthritis. The episodes of joint manifestations followed an irregular pattern, being most commonly reported with vaccine A. Just under two-thirds (65%) of the cases occurred in girls. The other systemic reactions observed in children during the follow-up period of this study are shown in Table 3.

Six children required hospitalization, all of them from Porto Alegre. The primary cause for three hospitalizations (mesenteric adenitis, appendicitis, and bronchopneumonia) was not related to the vaccine. From the three cases of aseptic meningitis related with mumps virus, case 1 (vaccine A) was associated with the vaccine virus, case 2 (control) with the wild virus, and in case 3 (vaccine A), the investigators concluded that the clinical and epidemiological data did not make it possible to define a single association, either with the vaccine virus or with the wild virus. Due to operational problems, the isolation and analysis of nucleotide sequencing for virus identification could not be performed. No severe reactions, such as anaphylactic shock or thrombocytopenic purpura, occurred.

**DISCUSSION**

The rate of clinical events, including local and systemic reactions observed after the administration of three different MMR vaccines, was determined on the basis of strict monitoring of the children for 30 days following vaccination and was compared with the frequency of adverse events in the control group. When comparing the vaccinated groups and the control group, we found that the frequency of clinical reactions was significantly higher among the vaccinees.

Vaccine A was found to induce more reactions than the other two vaccines. Vaccine A presented a statistically significant difference when compared with vaccine B concerning induration, nausea, cough, lymphadenopathy, and increased parotid volume. Vaccine A also presented a statistically significant difference when compared with vaccine C for induration, fever, lymphadenopathy, and increased parotid volume.

Vaccine C was found to induce more reactions than vaccine B concerning nausea, conjunctivitis, and increased parotid volume.

Although we found statistically significant differences for fever, nausea, and cough when comparing the three different vaccines, the differences were small. In contrast, with lymphadenopathy and increased parotid volume, we found moderate differences.

Headache was the most commonly reported manifestation among the three vaccinated groups, with no significant difference among them. However, with fever, there was a significant difference in incidence between vaccine A (5.5%) and vaccine C (4.2%). The temporal pattern that we found with fever differed from what other researchers have found. In our study, the fever began and showed a higher incidence in the first 5 days following vaccination. In contrast, other researchers have found the fever occurring 5 to 15 days after vaccination (13–17).

Concerning joint manifestations, the only symptom that we observed among the vaccinated children was arthralgia (65% among females), with no case of arthritis. The incidence rates for arthralgia that we found (0.4% with vaccine A, 0.4% with vaccine B, and 0.3% with vaccine C) are consistent with data from other reports, which indicate a 0.5% incidence in children (18), and with a higher incidence among girls (2, 19, 20).

We observed a low incidence of skin rash in the three vaccinated groups: 0.5% with vaccine A, 0.4% with vaccine B, and 0.7% with vaccine C, with no significant difference among them. In comparison to the rates that we found, other studies have found higher rates, ranging from 5% to 15% (4, 13–15).

We believe that the pre-existence of immunity, particularly to measles, had a direct impact on the rates of post-immunization adverse events, such as with fever and rash, that we observed in the students (21). In our pre-immunization serologic evaluation we found that the immunity for measles, mumps, and rubella was 87%, 73%, and 56%, respectively. Several factors help explain the previous immunity: routine immunization against measles since 1973, a campaign for general immunization against measles for children ranged 9 months to 14 years in 1992 (with coverage of 100% in Rio Grande do Sul), and an epidemic-

### Table 4. Relative risk (RR) and 95% confidence interval (CI) for lymphadenopathy and increased parotid volume, in study evaluating the adverse reaction potential of three measles-mumps-rubella combination vaccines, Rio Grande do Sul, Brazil, 1996

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>A/B RR (95% CI)</th>
<th>A/C RR (95% CI)</th>
<th>C/B RR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lymphadenopathy</td>
<td>3.11 (1.78–5.45)</td>
<td>2.22 (1.35–3.66)</td>
<td>1.40 (0.74–2.66)</td>
</tr>
<tr>
<td>Increased parotid volume</td>
<td>5.72 (3.11–10.54)</td>
<td>2.33 (1.52–3.58)</td>
<td>2.46 (1.26–4.80)</td>
</tr>
</tbody>
</table>

*P < 0.001.
*P < 0.002.
*P < 0.01.
The endemic pattern of the three diseases in all of Brazil.

The episodes of lymphadenopathy and of increased parotid volume presented larger variations in frequency among the three vaccines than was true for the other systemic adverse events.

The constituent mumps strains of the vaccines studied—Leningrad-Zagreb, Jeryl Lynn, and Urabe AM-9—had incidence rates, respectively, of 3.1%, 0.5%, and 1.3% for increased parotid volume. Other researchers have described similar results (5, 8).

We found that vaccine A presented a significantly greater risk for developing both lymphadenopathy and increased parotid volume, with the lowest risk being associated with vaccine B (Table 4).

Three cases of aseptic meningitis were detected among the children in the study, but only one case of vaccine-related aseptic meningitis was identified, among the children receiving vaccine A. This corresponds to one case among the 2,226 doses of this vaccine delivered. Nevertheless, due to the limitation of our sample size, we could not determine what the incidence of vaccine-associated aseptic meningitis would be in larger population groups. This event is commonly associated with the mumps strain (1–3, 5–7, 9). However, in the literature that we reviewed (8, 10), we found no papers describing the occurrence of meningitis following the use of the Leningrad-Zagreb mumps strain, the constituent of vaccine A.

We found vaccine A to cause more reactions than did the two other vaccines, especially in comparison to vaccine B. In addition, vaccine A presented both a temporal and cause-and-effect association with one case of aseptic meningitis.

These results had not yet been disclosed when, in 1997, an epidemic of measles occurred in Brazil. Some states had to conduct mass vaccination campaigns, and the states used two of the MMR vaccines that we had studied, vaccine A and vaccine C. Thousands of doses were applied in a short period of time. After the campaigns, there was a significant increase in post-vaccination adverse events, among them many cases of aseptic meningitis (22, 23). The estimated risk of aseptic meningitis found associated with vaccine A in Rio Grande do Sul was 1 case per 3,390 applied doses (22). In the city of Salvador, Bahia, the risk associated with vaccine C was 1 case per 14,000 applied doses (23). These mass vaccination campaigns allowed rare adverse events to be quickly detected.

We believe that when public health authorities need to choose MMR vaccines to use in national immunization programs, those officials must be aware of the safety and the efficacy of the various strains. This is especially true with mass vaccination strategies. We hope that our study has contributed information that will help public health authorities to make appropriate decisions.

Acknowledgments. In Brazil, we thank the National Immunization Program, the National Health Foundation, and the Ministry of Health, which supported this research project. We also thank the three laboratories—Serum Institute of India, Merck-Sharp-Dohme, and the Institute Pasteur Merieux—that provided the vaccines.

REFERENCES

16. Dunlop JM, RaiChoudhury K, Roberts JSC, Bryett KA. An evaluation of measles, mumps and rubella vaccine in a population of...
Objetivos. Comparar la incidencia de acontecimientos adversos tras la administración de tres vacunas combinadas contra el sarampión, la parotiditis y la rubéola que ya están en el mercado.

Métodos. En 1996 se realizó un ensayo clínico aleatorizado, doblemente enmascarado, en el que participaron 10 142 estudiantes de 6 a 12 años del estado de Rio Grande do Sul, Brasil. Las vacunas utilizadas contenían: A) las cepas Edmonston-Zagreb, Leningrado-Zagreb y RA 27/3A; B) las cepas Moraten, Jeryl Lynn y Wistar 27/3; y C) las cepas Schwartz, Urabe AM-9 y Wistar 27/3. La vacuna A se administró a 2 226 niños (21,9%), la B a 2 216 (21,8%), y la C a 2 179 (21,5%). El grupo de control lo formaron 3 521 niños (34,7%) no vacunados. Todos los participantes fueron observados diariamente durante 30 días para detectar posibles manifestaciones clínicas.

Resultados. Los acontecimientos adversos fueron más frecuentes en los niños vacunados que en el grupo de control ($P < 0,01$). El riesgo relativo (RR) de tumefacción parotídea con la vacuna A fue de 5,72 (intervalo de confianza del 95% [IC95]: 3,11 a 10,54) en comparación con la vacuna B, y de 2,33 (IC95: 1,52 a 3,58) en comparación con la vacuna C. La vacuna A también se asoció a un mayor riesgo de linfadenopatía que las vacunas B (RR = 3,11; IC95: 1,78 a 5,45) y C (RR = 2,22; IC95: 1,35 a 3,66). La vacuna C se asoció a un mayor riesgo de tumefacción parotídea que la vacuna B (RR = 2,46; IC95: 1,26 a 4,80). En los niños vacunados se detectaron tres casos de meningitis aséptica, pero solo uno, que recibió la vacuna A, se relacionó con la vacuna.

Conclusions. Las tres vacunas estimadas se asociaron a diferentes riesgos de acontecimientos adversos. La vacuna A causó más reacciones que las otras dos, en particular más que la vacuna B. Además, la vacuna A presentó una asociación temporal y causal con un caso de meningitis aséptica. Este estudio aporta información que puede ser utilizada para elegir vacunas contra el sarampión, la parotiditis y la rubéola a base de cepas eficaces y seguras, especialmente para la vacunación en masa.